首页> 美国卫生研究院文献>Brazilian Journal of Microbiology >Synergistic effects of sulbactam in multi-drug-resistantAcinetobacter baumannii
【2h】

Synergistic effects of sulbactam in multi-drug-resistantAcinetobacter baumannii

机译:舒巴坦在多药耐药中的协同作用鲍曼不动杆菌

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Acinetobacter baumannii is a frequently isolated etiologic agent of nosocomial infections, especially in intensive care units. With the increase in multi-drug resistance of A. baumannii isolates, finding appropriate treatment alternatives for infections caused by these bacteria has become more difficult, and available alternate treatments include the use of older antibiotics such as colistin or a combination of antibiotics. The current study aimed to evaluate the in vitro efficacy of various antibiotic combinations against multi-drug resistant A. baumannii strains. Thirty multi-drug and carbapenem resistant A. baumannii strains isolated at the Ankara Training and Research Hospital between June 2011 and June 2012 were used in the study. Antibiotic susceptibility tests and species-level identification were performed using conventional methods and the VITEK 2 system. The effects of meropenem, ciprofloxacin, amikacin, tigecycline, and colistin alone and in combination with sulbactam against the isolates were studied using Etest (bioMérieux) in Mueller-Hinton agar medium. Fractional inhibitory concentration index (FIC) was used to determine the efficacy of the various combinations. While all combinations showed a predominant indifferenteffect, a synergistic effect was also observed in 4 of the 5 combinations. Synergywas demonstrated in 43% of the isolates with the meropenem-sulbactam combination, in27% of the isolates with tigecycline-sulbactam, and in 17% of the isolates withcolistin-sulbactam and amikacin-sulbactam. No synergy was detected with thesulbactam-ciprofloxacin combination and antagonism was detected only in thesulbactam-colistin combination (6.66% of the isolates). Antibiotic combinations canbe used as an alternative treatment approach in multi-drug resistant A.baumannii infections.
机译:鲍曼不动杆菌是医院感染的经常分离的病原体,尤其是在重症监护病房中。随着鲍曼不动杆菌菌株的多药耐药性的增加,为由这些细菌引起的感染寻找合适的治疗替代方案变得更加困难,并且可用的替代治疗包括使用较旧的抗生素,例如粘菌素或抗生素的组合。当前的研究旨在评估各种抗生素组合对多重耐药的鲍曼不动杆菌的体外功效。在研究中使用了2011年6月至2012年6月间在安卡拉培训和研究医院分离出的30种耐多药和碳青霉烯类鲍曼不动杆菌菌株。使用常规方法和VITEK 2系统进行了抗生素敏感性测试和物种水平鉴定。在Mueller-Hinton琼脂培养基中使用Etest(bioMérieux)研究了美罗培南,环丙沙星,丁胺卡那霉素,替加环素和粘菌素单独使用以及与舒巴坦合用对分离物的影响。分数抑制浓度指数(FIC)用于确定各种组合的功效。虽然所有组合都表现出明显的冷漠在5种组合中的4种中也观察到了协同作用。协同作用在美罗培南-舒巴坦组合中,有43%的分离株证实含有替加环素-舒巴坦的分离株占27%,含有大肠菌素舒巴坦和阿米卡星舒巴坦。没有发现与舒巴坦-环丙沙星联合用药和拮抗药仅在舒巴坦-colistin组合(6.66%的分离物)。抗生素组合可以用作耐多药A的替代治疗方法。鲍曼氏菌感染。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号